Needham Maintains Buy on Revolution Medicines, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $46 to $62.

July 16, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines and raises the price target from $46 to $62.
The raised price target from $46 to $62 by a reputable analyst suggests increased confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100